BOLDER II study confirms therapeutic potential of SEROQUEL in bipolar depression (EurekAlert!)Alderley
BOLDER II study confirms therapeutic potential of SEROQUEL in bipolar depression (EurekAlert!)
Alderley Park, Cheshire, UK, 21 October 2005: - Newly released top-line results from the BOLDER II (BipOLar DEpRession) study have underlined the potential for SEROQUEL (quetiapine fumarate) in the treatment of patients with major depressive episodes associated with bipolar disorder.
Counseling Center to offer depression screenings today (Indiana Statesman)
Depression is a disorder that can affect up to 10 percent of the American population at any given time, according to WebMD.com. ISU's Student Counseling Center is giving ISU students the chance to participate in National Depression Screening Day …
Depression alone affects approximately 1.3 million Australian women ever year (News-Medical-Net)
Women's health problems, depression and child abuse represented a major health crisis in Australia, a seminar focusing on women and mental health over the weekend was told.
